BGJ398 (erdafitinib)

erdafitinib · Janssen Biotech, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BGJ398 (erdafitinib), covering 2026-02-09 to 2026-02-09. Get the full timeline:

Most recent: Clinical Trial Update: BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder [NA]